
Three-year follow up results from the TheraP study for people with metastatic prostate cancer shows continued benefits
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) reports the three-year follow up results of its TheraP (ANZUP 1603) clinical trial